Page last updated: 2024-12-05

3-xylene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

m-xylene : A xylene carrying methyl groups at positions 1 and 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7929
CHEMBL ID286727
CHEBI ID28488
MeSH IDM0098405

Synonyms (78)

Synonym
m-xylenes
m-methyltoluene
1,3-dimethylbenzol
CHEBI:28488 ,
3-xylene
meta-xylene ,
m-dimethylbenzene
nsc61769
m-xylol
wln: 1r c1
nsc-61769
2,4-xylene
einecs 272-684-0
santosol 150
benzene,1,3-dimethyl
inchi=1/c8h10/c1-7-4-3-5-8(2)6-7/h3-6h,1-2h
benzene, 1,3-dimethyl-
NCGC00091711-01
hsdb 135
einecs 203-576-3
benzene, m-dimethyl-
ai3-08916
ccris 907
xylene, m-
nsc 61769
m-xylene
108-38-3
1,3-xylene
C07208
1,3-dimethylbenzene
m-xylene, anhydrous, >=99%
m-xylene [un1307] [flammable liquid]
CHEMBL286727 ,
BMSE000554
X0013
S0648
bdbm50008556
AKOS000121123
NCGC00091711-03
NCGC00091711-02
tox21_303203
NCGC00257052-01
cas-108-38-3
dtxsid6026298 ,
dtxcid501446
cas-1330-20-7
tox21_200292
NCGC00259605-01
tox21_202056
dsstox_gsid_21446
NCGC00257846-01
dsstox_rid_76162
dsstox_cid_1446
unii-o9xs864hte
o9xs864hte ,
ec 203-576-3
FT-0629041
STL268867
m-xylene [mi]
3-xylene [hsdb]
J-503933
metaxylene
m-xylene-alpha,alpha,alpha,alpha',alpha',alpha'-d6
mfcd00008536
F1908-0174
m-xylene, analytical standard
m-xylene, puriss. p.a., >=99.0% (gc)
m-xylene, saj first grade, >=98.5%
m-xylene, reagentplus(r), 99%
m-xylene, for synthesis, 99%
m-xylene, pharmaceutical secondary standard; certified reference material
m-xylene 100 microg/ml in methanol
m-xylene 10 microg/ml in methanol
Q3234708
m xylene
1,3-dimethyl-benzene
EN300-24548
m-xylene-alpha,alpha'-13c2

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Results obtained in condition of acute and subchronic inhalation exposure and toxicokinetics data interpreted jointly indicate the more than additive toxic effects of combined exposure to toluene and m-xylene."( Toxic effects of combined exposure to toluene and m-xylene in animals. III. Subchronic inhalation study.
Górny, R; Korsak, Z; Sokal, JA, 1992
)
0.28
" It may be concluded that changes in the hepatocytes ultrastructure were an adaptive rather than a toxic effect."( The toxic effects of combined exposure to toluene and m-xylene in animals. IV. Liver ultrastructure after subchronic inhalatory exposure.
Jedlińska, U; Korsak, Z; Rydzyński, K; Sokal, JA, 1992
)
0.28
" Study results may suggest that, reported earlier, the more than additive toxic effects of combined exposure to m-xylene and toluene in animals may result from its metabolic interaction."( The toxic effects of combined exposure to toluene and m-xylene in animals. II. Blood toluene and m-xylene during single and combined exposure in rats.
Korsak, Z; Sokal, JA; Swiercz, R, 1991
)
0.28
" Thus, in condition of combined exposure, the toxic effect of m-xylene was not added to the effect of n-butyl alcohol."( Toxic effects of subchronic combined exposure to n-butyl alcohol and m-xylene in rats.
Korsak, Z; Swiercz, R; Wiśniewska-Knypl, J, 1994
)
0.29
" Based on this method, a biologically-based mathematical model could be used to determine an equivalent external dose for a specific toxic end point."( Improved method for in vitro assessment of dermal toxicity for volatile organic chemicals.
McDougal, JN; Rogers, JV, 2002
)
0.31
" Since VOCs are used in industrial, commercial and military applications, concern is mounting with respect to VOC safe exposure limits."( The effect of m-xylene on cytotoxicity and cellular antioxidant status in rat dermal equivalents.
Coleman, CA; Hull, BE; McDougal, JN; Rogers, JV, 2003
)
0.32
"In vitro models are being used to evaluate the toxic and irritating effects of JP-8, a kerosene-based jet fuel."( The cytotoxicity of volatile JP-8 jet fuel components in keratinocytes.
McDougal, JN; Pollard, DL; Rogers, JV; Rooney, AD; Siegel, GL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
"The objective of the present study was to develop a physiologically based pharmacokinetic (PBPK) model for a ternary mixture of alkyl benzenes [toluene (TOL), m-xylene (XYL), and ethylbenzene (EBZ)] in rats and humans."( Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans.
Brodeur, J; Charest-Tardif, G; Krishnan, K; Tardif, R, 1997
)
0.3
" Experimental results were compared with simulation results of a physiologically based pharmacokinetic (PB-PK) model."( Ethnic differences in biological monitoring of several organic solvents. II. A simulation study with a physiologically based pharmacokinetic model.
Droz, PO; Jang, JY, 1997
)
0.3
"A physiologically-based pharmacokinetic model, containing a skin compartment, was derived and used to simulate experimentally determined exposure to m-xylene, using human volunteers exposed under controlled conditions."( Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis.
Akrill, P; Cocker, J; Dyne, D; Jones, K; Loizou, GD, 1999
)
0.3
"A physiologically based pharmacokinetic model of the transfer of organic solvents in rat bodies was developed."( Development of a physiologically based pharmacokinetic model of organic solvent in rats.
Horiuchi, J; Kaneko, T; Sato, A, 2000
)
0.31
" The toxicokinetics of these biomarkers following inhalation exposure have yet to be described by physiologically based pharmacokinetic (PBPK) modeling."( Human inhalation exposures to toluene, ethylbenzene, and m-xylene and physiologically based pharmacokinetic modeling of exposure biomarkers in exhaled air, blood, and urine.
Aranda-Rodriguez, R; Haddad, S; Marchand, A; Nong, A; Tardif, R, 2015
)
0.42
" Physiologically based pharmacokinetic models for adults (AD), neonates (NEO), toddlers (TODD), and pregnant women (PW) were used to simulate inhalation exposure to "low" (RfC-like) or "high" (AEGL-like) air concentrations of benzene (Bz) or dichloromethane (DCM), along with various levels of toluene alone or toluene with ethylbenzene and xylene."( Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.
Haddad, S; Valcke, M, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of soil-adsorbed m-xylene was assessed in male and female rats gavaged with an aqueous suspension of 14C-m-xylene alone or adsorbed to sandy or clay soil."( Sex differences in the bioavailability of soil-adsorbed m-xylene in orally exposed rats.
Abdel-Rahman, MS; Kadry, AR; Skowronski, GA; Turkall, RM, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" JP-8 components are volatile, which makes in vitro studies difficult to evaluate dose-response relationships due to changes in chemical dosimetry caused by evaporation from the exposure medium."( The cytotoxicity of volatile JP-8 jet fuel components in keratinocytes.
McDougal, JN; Pollard, DL; Rogers, JV; Rooney, AD; Siegel, GL, 2004
)
0.32
" This study examined the dose-response and durational effects of m-xylene inhalation on cytochrome P-450 activities in the respiratory tract and liver as well as the effects of these CYP450 alterations on 1-nitronaphthalene (1-NN)-induced respiratory or hepatic toxicity."( Inhibition of rat respiratory-tract cytochrome P-450 activity after acute low-level m-xylene inhalation: role in 1-nitronaphthalene toxicity.
Foy, JW; Schatz, RA, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
xylene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
m-xylene degradation (anaerobic)310
1,3-dimethylbenzene degradation to 3-methylbenzoate39

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.00300.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency15.35530.000714.592883.7951AID1259369
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency29.91490.000657.913322,387.1992AID1259378; AID1259394
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.00250.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency41.13600.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency53.11100.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.01700.000229.305416,493.5996AID743075; AID743077; AID743079
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency61.64480.023723.228263.5986AID743223
activating transcription factor 6Homo sapiens (human)Potency0.23810.143427.612159.8106AID1159516
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Nuclear receptor ROR-gammaHomo sapiens (human)Potency7.49780.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)2.45100.00000.933210.0000AID32248; AID32280
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EndolysinTequatrovirus T4Kd364.00003.00003.00003.0000AID238119
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID32248Inhibition of acetylcholinesterase.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.
AID24226Partition coefficient (logP)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID238119Dissociation constant against T4 lysozyme mutant L99A2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Decoys for docking.
AID1145576Octanol-water partition coefficient, log P of the compound1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Partition coefficients and surface areas of some alkylbenzenes.
AID162229Toxicity determined using Konemann's Industrial Pollutants Toxicity Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID32280IC50 against acetylcholinesterase; value ranges from 1-4900 nM.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (212)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (16.98)18.7374
1990's49 (23.11)18.2507
2000's51 (24.06)29.6817
2010's61 (28.77)24.3611
2020's15 (7.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.49 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index38.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.37%)5.53%
Reviews5 (2.28%)6.00%
Case Studies1 (0.46%)4.05%
Observational0 (0.00%)0.25%
Other210 (95.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]